Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution

DeVillez, R. L.

doi:10.1001/archderm.130.3.303

Cited by 53 publications

(55 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In otherwise healthy women, female-pattern hair loss (FPHL) is the most frequent cause of telogen effluvium and is usually successfully treated with topical minoxidil [2,3,4]. Special attention is also given to the use of a contraceptive pill or hormonal replacement therapy, since gestagens with proandrogenic effect may exacerbate hair loss and are consequently contraindicated in these women.…”

Section: Introductionmentioning

confidence: 99%

Seasonality of Hair Shedding in Healthy Women Complaining of Hair Loss

2009

View full text Add to dashboard Cite

Background: A number of otherwise healthy women with or without clinical alopecia complain of recurrent hair loss, presumably reflecting seasonality in the growth and shedding of hair. Objective: To test the hypothesis that periodicity in hair shedding reflects seasonal changes in human hair growth. Methods: Retrospective case study over a period of 6 years of apparently healthy women with the complaint of hair loss. All underwent biochemical investigations, and trichograms were made. Results: After exclusion of patients with a disease or on drugs known to cause hair loss, 823 women remained. Analysis of trichograms demonstrated annual periodicity in the growth and shedding of hair, manifested by a maximal proportion of telogen hairs in summer. A second peak seems to exist, though it is less pronounced, in spring. The telogen rates were lowest in late winter. Conclusions: These results confirm the findings of former authors who have indicated seasonal changes in human hair growth, though this is the first study performed systematically in a representative number of women.

show abstract

Section: Introductionmentioning

confidence: 99%

Seasonality of Hair Shedding in Healthy Women Complaining of Hair Loss

2009

View full text Add to dashboard Cite

show abstract

“…[2] None of the pharmacological treatments for FPB result in full hair recovery, and they are therefore used indefinitely to prolong their effect. [22] Similarly, the management of hirsutism requires ongoing treatment with cosmetic (e.g. topical eflornithine hydrochloride) and physical measures (such as electrolysis, laser hair removal) and or hormonal therapy.…”

Section: Discussionmentioning

confidence: 99%

Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders

Vázquez

Amayuelas

Lamarca

et al. 2011

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

The diagnosis and management of four cases of dermatological disorders, most of which are related to the endocrine disorder of androgen excess, are presented. Combined oral contraceptives (COCs) may be useful when well-tolerated hormonal therapy and or when contraception is required. A female patient with androgenetic alopecia or female pattern balding, without underlying hyperandrogenism, was treated with ethinylestradiol chlormadinone acetate (EE CMA) 0.03 mg 2 mg for 6 months and experienced stabilization of hair loss (case report 1). A patient who had previously received a COC for an irregular menstrual pattern but again experienced irregular menses and also acne after stopping treatment was diagnosed with acne associated with polycystic ovary syndrome (PCOS) [case report 2]. After 6 month's treatment with EE CMA 0.03 mg 2 mg, this patient had fewer acne lesions and became eumenorrheic. A third patient who had excess hair since childhood was diagnosed with idiopathic hirsutism (no underlying gynecological or endocrinological disorder was found) and was treated with EE CMA 0.03 mg 2 mg (case report 3). Less hair growth was reported after 6 months' treatment. Case report 4 describes a patient who presented with oligomenorrhea and acne. She was diagnosed with PCOS with acne, seborrhea and mild hirsutism. Treatment with EE CMA 0.03 mg 2 mg for 6 months resulted in improvements in her facial acne, seborrhea and hirsutism; she also became eumenorrheic. These four cases illustrate that EE CMA may be a useful and well tolerated treatment option in the management of patients with dermatological disorders with or without hyperandrogenization.

show abstract

“…This was comparable with Richard L, et al study in which 20 % showed moderate response. 17 Patient"s own assessment at 6 months showed excellent improvement in 60% (n=18) patients who were on Group B (minoxidil + PRP), while it was only 33.33% (n=10) patients of Group A (Only minoxidil). No improvement was seen in 2 patient of Group B (minoxidil + PRP) and moderate improvement was seen in 8 patients in group B which was same as in Group A (minoxidil only).…”

Section: Figure 7: Type Of Hair Growth In Patients At 6 Monthsmentioning

confidence: 91%